Modifi Bio logo 2022-07-25.png
Modifi Biosciences Acquired by Merck
23 oct. 2024 07h05 HE | Modifi Biosciences
NEW HAVEN, Conn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Modifi Biosciences, Inc. (“Modifi Biosciences”), a leader in the development of direct DNA modification enabled cancer therapeutics, today...
ModifiBioLogo__Blue-Teal_RGB_579 × 217.png
Modifi Bio Raises Additional $4.3 Million in Seed Funding
16 oct. 2023 07h00 HE | Modifi Biosciences
NEW HAVEN, Conn., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced the closing of $4.3 million in a second...
Modifi Bio logo 2022-07-25.png
Modifi Bio Announces Scientific Advisory Board
13 déc. 2022 08h30 HE | Modifi Biosciences
NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, today announced its Scientific Advisory Board, with the...
Modifi Bio logo 2022-07-25.png
Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform
25 oct. 2022 08h00 HE | Modifi Biosciences
NEW HAVEN, Conn., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences, a leader in direct DNA modification developing novel cancer therapeutics, has been selected by the National Cancer Institute...
Modifi Bio logo 2022-07-25.png
Science Publication First to Describe Modifi Bio’s Novel Approach to Fight Cancer Cells with DNA Modification
28 juil. 2022 14h11 HE | Modifi Biosciences
NEW HAVEN, Conn., July 28, 2022 (GLOBE NEWSWIRE) -- Modifi Biosciences announced today that the journal Science has published a critical study validating the company’s novel oncology platform based...